Beyond the Static Pipeline: Live Asset Orchestration in Biopharma

The biopharmaceutical industry operates at the bleeding edge of human innovation, yet its strategic frameworks often lag behind. For too long, the industry has relied on static, linear pipeline management—a model increasingly unsuited for an era defined by scientific breakthroughs, rapid market shifts, and unforeseen global challenges. The reality is that a static strategy in a dynamic world is a dead strategy. The imperative now is to embrace Live Asset Orchestration, treating every drug candidate, research program, and commercialized therapy not as a fixed point, but as a dynamic asset within a continuously evolving ecosystem.

The Erosion of the Traditional Pipeline

Biopharma firms face unprecedented pressures: escalating R&D costs, declining return on investment, and intense competitive dynamics. Boston Consulting Group (BCG) reported that average total shareholder return (TSR) across the biopharma sector flatlined at 0% from 2021 to 2025, significantly underperforming the broader market. This stagnation underscores a fundamental challenge: the traditional business model is under pressure across every facet of the value chain.

The linear approach to drug development—from discovery to clinical trials to commercialization—struggles to adapt to new modalities, regulatory shifts, and emergent therapeutic areas. Talent shortages, data fragmentation, and rising regulatory demands further complicate execution, highlighting that success depends not just on breakthrough science, but on the operational foundations that support it. In such an environment, the financial cost of slow execution can be staggering. To truly understand this impact, explore how delays ripple through an organization with our Strategy Drag Calculator.

Moderna: Architecting a Platform for Continuous Evolution

Moderna exemplifies the shift from pipeline to platform. Initially defined by its groundbreaking mRNA COVID-19 vaccine, the company is strategically expanding its mRNA platform into a multi-product enterprise spanning infectious diseases, oncology, rare diseases, and autoimmune conditions. This isn't just diversification; it's a modular, platform-centric strategy.

Moderna's "Horizon" programs—Horizon 1 for approved/late-stage products, Horizon 2 for emerging modalities, and Horizon 3 for future innovations—demonstrate a commitment to balancing near-term growth with long-term invention. By leveraging data, AI, machine learning, and robotics, Moderna aims to accelerate discovery and continuously improve its execution across these horizons. This approach allows for rapid iteration and application of a core technology across diverse therapeutic areas, effectively orchestrating a live portfolio of mRNA assets.

Eli Lilly: Acquisitive Velocity for Strategic Diversification

Eli Lilly's recent strategic maneuvers highlight another facet of live asset orchestration: aggressive, targeted M&A to rapidly diversify and fortify its portfolio. Driven by the immense success of its GLP-1 drugs like Mounjaro/Tirzepatide, Lilly embarked on an acquisition spree in 2026, committing over $25 billion across numerous deals.

These acquisitions are not scattershot but are aimed at expanding Lilly's presence in high-growth areas like oncology (e.g., in vivo CAR-T therapies with Orna and Kelonia Therapeutics), sleep disorders, and inflammatory diseases. This rapid, data-informed capital allocation demonstrates a live strategy at work, leveraging current successes to build new, diversified growth engines and mitigate future patent cliffs. It's a testament to turning financial capital into live strategic optionality, a concept further explored in our article, AI-Native Pharma: Turning Novartis, Lilly and Pfizer into Live Strategy Engines.

Merck: Pillars of Resilience Beyond a Blockbuster

Merck faces the strategic challenge of preparing for the impending patent expiration of its blockbuster oncology drug, Keytruda, around 2028. Its response is a multi-pronged approach to live asset orchestration, focusing on a "One Pipeline" strategy that integrates internal discovery with external innovation through business development and licensing.

Merck's oncology R&D strategy includes three key pillars, prominently featuring a collaboration with Moderna on the mRNA-4157 cancer vaccine, which is being evaluated alongside Keytruda to enhance immune responses. Beyond oncology, Merck is actively diversifying its portfolio with advancements in respiratory disease prevention and pneumococcal vaccination, recognizing that long-term enterprise stability requires multiple durable growth platforms. This strategic foresight, leveraging organizational design as a lever for value protection and growth, embodies live strategy in action.

The enablegrowth Imperative: Pillars of Live Asset Orchestration

For biopharma to truly thrive, strategy must transcend static planning and become a dynamic operating system. At enablegrowth, our Strategy OS is built on principles that enable this transformation:

• Intelligence-Augmented (IA) Decisions: AI should augment, not replace, the human strategist. Real-time telemetry, powered by AI, enables human leaders to make informed, nuanced decisions, incorporating institutional memory and 'Locked Human Edits' rather than blindly following automated outputs.
• Real-Time Portfolio Calibration: Annual reviews are obsolete. Organizations need continuous market pulse signals and automated staleness alerts to calibrate R&D investments, manufacturing capacities, and commercial strategies in real-time. This ensures that resources are always aligned with the most promising opportunities and evolving scientific landscapes.
• Perspective-Pivot Engine (PPE): A company's strategic stance—Incumbent, Observer, or Disruptor—is not fixed. A live strategy system allows organizations to dynamically pivot their perspective, optimizing resource allocation and narrative control based on real-time competitive dynamics and scientific advancements. For instance, Eli Lilly's rapid acquisitions demonstrate an 'Incumbent' leveraging strength to become a 'Disruptor' in new therapeutic areas.
• Modular Strategic Frameworking: monolithic planning is inherently fragile. Strategy should be composed of decoupled, adaptable components that can be individually updated without destabilizing the entire enterprise. This modularity allows for rapid experimentation and iterative development, essential for navigating the complexities of drug discovery and commercialization. This is the essence of moving From Pipeline to Platform: Pharma Must Become Live.

The future of biopharma is not about merely having a pipeline; it's about orchestrating a live, adaptive ecosystem of assets. This requires a fundamental reimagining of how strategy is conceived, executed, and continuously refined. It demands a shift from planning to a perpetual state of dynamic calibration.

Are you ready to transform your strategic process from a static document into a living, breathing operating system that anticipates change and drives sustained growth? It's time to move beyond guesswork and into intelligence-augmented execution.

Join the waitlist for Strategy OS →